Levoketoconazole for treatment of congenital adrenal hyperplasia and primary aldosteronism
US12201632B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 9, 2021 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Aug 30, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods for treating congenital adrenal hyperplasia or primary aldosteronism in a subject in need thereof, comprising administering a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer to the subject. Also disclosed are compositions comprising a therapeutically effective amount of 2S,4R ketoconazole enantiomer substantially free of the 2R,4S ketoconazole enantiomer for use in treating a disease or condition associated with congenital adrenal hyperplasia or primary aldosteronism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.